CLOSE
MENU
Rogocekib for the treatment of Refractory or Relapsed Acute Myologic Lymphoma(AML) has been granted Orphan Drug Designation (ODD) in the US by the FDA
Jan 10, 2025
サブ-ナビゲーション
Company
CEO Message
Mission・2030 Vision
Leadership
Directors
Business Model
Brand Origin
Company Profile
Science/Pipleline
Focused Area
Pipeline Overview
CLK Inhibitor CTX-712
MALT1 Inhibitor CTX-177
CDK12 Inhibitor CTX-439
GCN2 Inhibitor CRD-1968099
News
Investor Relations
Management Policies
Financial Information
IR Library
Stock Information
IR Calender
現在位置:
IR News
IR FAQ
Disclaimer
Career
Contact
Contact
Privacy Policy
Term of use
Sitemap
Rogocekib for the treatment of Refractory or Relapsed Acute Myologic Lymphoma(AML) has been granted Orphan Drug Designation (ODD) in the US by the FDA
Jan 10, 2025
VIEW IR NEWS
ページの先頭へ
ページの先頭へ
menu
gnavi-box